ニュース

La Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy and Clinical Immunology, ...
Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue ...
The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of ...
Heald’s money-back guarantee boldly links business success to patient outcomes,” said Dr. Neal Patel, CIO at Vanderbilt ...
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells ...
Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information ...
Investors may submit written questions in advance of the conference call to [email protected] or through the webcast portal. A replay of the webcast will be available on the Company’s website at ...
It is important for shareholders to understand that these assets, including our intellectual property portfolio, drug development platforms, and proprietary artificial intelligence technology, are ...
RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...
The Inc. 5000 list represents the most successful independent businesses in the United States, highlighting innovation, resilience, and performance. Instinct’s placement reflects the company’s ...
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 ; CNTY-308, a CAR-iT ...